Inhaled mRNA therapy shows promise for rare lung disease
NCT ID NCT06633757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an inhaled mRNA therapy called RCT1100 in 14 adults with primary ciliary dyskinesia (PCD) caused by a specific genetic mutation (DNAI1). The goal was to see if the treatment could improve mucociliary clearance — the lungs' ability to clear mucus and germs. The study focused on safety and preliminary effectiveness to guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RCT1100 (mRNA therapy inhaled via nebulizer)
What this could lead to
If successful, this could point toward a treatment that improves lung clearance and respiratory function in people with PCD caused by DNAI1 mutations.
What could go wrong
This is a very early Phase 1b trial with only 14 participants, so results may not apply to all PCD patients. The therapy is still experimental and safety or efficacy are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA (PCD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Copenhagen University Hospital - Rigshospitalet
Copenhagen, 2100, Denmark
-
Münster University Hospital, Albert-Schweitzer-Campus 1
Münster, North Rhine-Westphalia, 48149, Germany
-
UNC
Chapel Hill, North Carolina, 27514, United States